We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Pooled Saliva Testing for COVID-19 Could Expand SARS-CoV-2 Testing Capacity

By LabMedica International staff writers
Posted on 21 Apr 2021
A new study supports the expansion of SARS-CoV-2 testing capacity by pooling saliva samples, an approach that can provide cost benefits to laboratories.

Researchers at the Yale School of Public Health (New Haven, CT, USA) analyzed the sensitivity of different numbers of saliva samples pooled together and found that although test sensitivity decreases, the pooled method may provide a more cost-effective method for SARS-CoV-2 testing. When conducting pooled testing, a negative result for an entire pool would indicate that all samples were below the limit of detection, but a positive result for the pool would lead to individual retesting of all samples.

Throughout the pandemic, the use of nasopharyngeal swabs as the standard testing method has presented both a logistical barrier - as they must be collected by trained personnel - but also a supply chain issue, since testing reagents and swabs are in low supply in certain areas. SalivaDirect, a set of open-source testing protocols developed at the School of Public Health which has been issued an Emergency Use Authorization from the US Food and Drug Administration, completely circumvents the complications of using nasopharyngeal swabs. Instead, it applies the RT-qPCR technique to saliva samples, driving down costs and decreasing stress on supply chains.

For their study, the researchers sought to go one step further in decreasing the cost of testing - pooling saliva samples in order to test multiple people simultaneously. The team used saliva collected from COVID-19 inpatients and at-risk healthcare workers. They then analyzed the saliva samples in pools of three different sizes - five, 10 and 20 samples per pool. They discovered that detection sensitivity, a test’s ability to designate an individual with disease as positive, decreased as pool size increased. With the pools of five samples, the sensitivity was reduced by 7.4%, as compared to testing on an individual sample. For 20-sample pools, there was a 14.8% reduction in this value. However, decreased sensitivity is expected with pooling samples, and the researchers concluded that this level of sensitivity could still be effective for accurate, large-scale screening of SARS-CoV-2.

The researchers also pointed out that the lower per-person cost of pooled testing may allow for more frequent testing, and thus a lower probability of two repeated false-negative results for any one person. In this way, pooling samples can be even more effective than individual testing, according to the study. In the future, the researchers hope to analyze the implementation of pooled testing to see if it actually helps communities reduce costs while adequately screening the members of the community. In doing so, researchers will be able to see the effects of pooled testing with a larger sample size than in their studies.

“Pooling is essential,” said Anne Wyllie, Associate Research Scientist in Epidemiology and researcher at the Yale School of Public Health. “We need to find ways to do mass testing that is affordable and can be widely accessible. Pooling is a natural strategy to bring test prices down and to test more samples overall.”

“Even though we might get a drop in sensitivity with pooling, depending on the prevalence in the particular environment in the particular population, it will still end up being a lot cheaper and very beneficial,” added Orchid Allicock, Postdoctoral Research Associate at the School of Public Health.

Related Links:
Yale School of Public Health


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Myeloperoxidase Assay
IDK MPO ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.